Activin and Inhibin

(-)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.Form:SolidIC50&amp: Target:retinoic acid.

(-)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.Form:SolidIC50&amp: Target:retinoic acid.

(-)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.IC50&amp: Target:retinoic acid.

(-)-TK216 is an enantiomer of TK216 ( HY-122903 ). TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor. (-)-TK216 has anti-cancer activity.In Vitro(-)-TK216 (compound 14: for 3 days) has an IC 50 &lt:5 μM in SKES cells

(-)-TK216 is an enantiomer of TK216 ( HY-122903 ). TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor. (-)-TK216 has anti-cancer activity.In Vitro(-)-TK216 (compound 14: for 3 days) has an IC 50 &lt:5 μM in SKES cells

(-)-TK216 is an enantiomer of TK216 ( HY-122903 ). TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor. (-)-TK216 has anti-cancer activity.In Vitro(-)-TK216 (compound 14: for 3 days) has an IC 50 &lt:5 μM in SKES cells

(-)-TK216 is an enantiomer of TK216 ( HY-122903 ). TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor. (-)-TK216 has anti-cancer activity.In Vitro(-)-TK216 (compound 14: for 3 days) has an IC 50 &lt:5 μM in SKES cells

(-)-TK216 is an enantiomer of TK216 ( HY-122903 ). TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor. (-)-TK216 has anti-cancer activity.In Vitro(-)-TK216 (compound 14: for 3 days) has an IC 50 &lt:5 μM in SKES cells

(-)-TK216 is an enantiomer of TK216 ( HY-122903 ). TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor. (-)-TK216 has anti-cancer activity.In Vitro(-)-TK216 (compound 14: for 3 days) has an IC 50 &lt:5 μM in SKES cells

(-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective JNKs inhibitor, with IC 50 s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1 , JNK2 and JNK3 , respectivelyIn Vitro(−)-zuonin A binds the D-recruitment site (DRS) of JNK, a

(1R)-Tenofovir amibufenamide ((1R)-HS-10234) is the isomer of Tenofovir amibufenamide, is an orally active antiviral agent. (1R)-Tenofovir amibufenamide ((1R)-HS-10234) is a HIV infection inhibitor and HBV infection inhibitor. (1R)-Tenofovir

(1R)-Tenofovir amibufenamide ((1R)-HS-10234) is the isomer of Tenofovir amibufenamide, is an orally active antiviral agent. (1R)-Tenofovir amibufenamide ((1R)-HS-10234) is a HIV infection inhibitor and HBV infection inhibitor. (1R)-Tenofovir